Medicine and Dentistry
COVID-19
100%
Pediatrics
79%
Child
76%
Severe Acute Respiratory Syndrome Coronavirus 2
31%
Human Respiratory Syncytial Virus
29%
Systematic Review
29%
Prophylaxis
29%
Childhood
29%
Influenza
29%
Mortality
23%
Infant
23%
Intensive Care
21%
Asthma
19%
Wheeze
19%
Cystic Fibrosis
19%
Antivirus Agent
19%
Gordonia
19%
Peritonitis
19%
Peritoneal Dialysis
19%
Diseases
14%
Virus
13%
Epithelium
12%
Intensive Care Unit
12%
Adolescent
12%
Diagnosis
11%
Pediatrics Patient
11%
Therapeutic Procedure
11%
Patient
10%
Monoclonal Antibody
10%
Innate Immunity
10%
Leukocyte
10%
Antimicrobial Therapy
9%
Epithelial Cell
9%
Childbirth
9%
Cell Culture
9%
Observation
9%
Community-Acquired Pneumonia
9%
Coronavirinae
9%
Life
9%
Monoclonal Antibody Therapy
9%
Neonates
9%
Circulation
9%
Fatality
9%
Low and Middle Income Countries
9%
Pediatric Surgery
9%
Antiinfective Agent
9%
Circumcision
9%
Protein
9%
Morphology
9%
Respiratory Syncytial Virus Infection
9%
Immunology and Microbiology
Human Respiratory Syncytial Virus
48%
Epithelium
14%
Age
13%
Innate Immune System
11%
Mortality
10%
Asthma
9%
Life
9%
Palivizumab
9%
Virus
9%
Respiratory Syncytial Virus Infection
9%
Birth
9%
Cell Culture
9%
Mutation
9%
Morphology
9%
Lower Respiratory Tract
9%
Upper Respiratory Tract
9%
Bacterium
9%
Childhood
9%
Circulation
9%
Spike
9%
Influenza
9%
Organisms
9%
Respiratory Virus
9%
Interferon Type I
9%
Cell Culture
9%
Interferon Gamma
9%
COVID-19
9%
Lipocalin-2
6%
Development
6%
Respiratory Syncytial Virus
6%
Monoclonal Antibodies
5%
Health
5%
Pharmacology, Toxicology and Pharmaceutical Science
Human Respiratory Syncytial Virus
38%
Diseases
20%
Influenza
19%
Palivizumab
19%
Mortality
13%
Respiratory Syncytial Virus Infection
9%
Coronavirinae
9%
Influenza
9%
Clinical Trial
9%
Wheezing
9%
Cystic Fibrosis
9%
Tolerability
9%
Asthma
9%
Drug
9%
Respiratory Virus
9%
Antiinfective Agent
9%
Human Respiratory Syncytial Virus
9%
Cohort Study
9%
Gamma Interferon
6%
Monoclonal Antibody
5%